MedTrace Logo

Study of ZIO-201 in Advanced Sarcoma

NCT00439686 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2014-01-31

No results posted yet for this study

Summary

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced sarcoma.

Conditions

  • Advanced Sarcoma

Interventions

DRUG

ZIO-201

ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months

Sponsors & Collaborators

  • Alaunos Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jonathan Lewis, MD, PhD · ZIOPHARM Oncology, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-06-30
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439686 on ClinicalTrials.gov